MARKET

ALKS

ALKS

Alkermes Plc
NASDAQ
32.90
-0.26
-0.78%
After Hours: 32.41 -0.49 -1.49% 17:36 02/17 EST
OPEN
32.81
PREV CLOSE
33.16
HIGH
33.74
LOW
32.60
VOLUME
1.58M
TURNOVER
--
52 WEEK HIGH
36.45
52 WEEK LOW
25.17
MARKET CAP
5.43B
P/E (TTM)
16.26
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALKS last week (0209-0213)?
Weekly Report · 1d ago
Is It Time To Reassess Alkermes (ALKS) After Mixed Share Price Performance?
Simply Wall St · 2d ago
Assessing Alkermes (ALKS) Valuation After Recent Share Price Swings
Simply Wall St · 4d ago
Alkermes Reshapes Portfolio With Avadel Deal And US$1.5b Debt Shift
Simply Wall St · 5d ago
Avadel Pharmaceuticals Shares Delisted from Nasdaq Following Acquisition
Reuters · 5d ago
Alkermes Completes Acquisition of Avadel Pharmaceuticals
Reuters · 5d ago
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
Barchart · 6d ago
Alkermes plc to Report Financial Results and Outline 2026 Expectations
Reuters · 6d ago
More
About ALKS
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Webull offers Alkermes Plc stock information, including NASDAQ: ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.